Akamai Technologies (NASDAQ:AKAM) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.31 by 3.05 percent. This is a 4.93 percent decrease over earnings of $1.42 per share from the same period last year. The company reported quarterly sales of $903.00 million which beat the analyst consensus estimate of $898.14 million by 0.54 percent. This is a 5.88 percent increase over sales of $852.82 million the same period last year.
Champions Oncology Announces A Multi-Year Agreement And Strategic Collaboration With BioVolume To Transform Reproducibility In Preclinical Oncology Efficacy Studies
Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, today announced an agreement to adopt BioVolume's
